Bypassing glycosylation: engineering aglycosylated full-length IgG antibodies for human therapy
- PMID:21420850
- DOI: 10.1016/j.copbio.2011.03.002
Bypassing glycosylation: engineering aglycosylated full-length IgG antibodies for human therapy
Abstract
In recent years a number of aglycosylated therapeutic antibodies have entered the clinic. The clinical evaluation of these antibodies has served to dispel concerns that the absence of the ubiquitous N297 glycan in the Fc of IgG might result in immunogenicity, poor in vivo stability or unfavorable pharmacokinetics. Importantly, recent studies have now demonstrated that aglycosylated antibodies can be engineered to display novel effector functions and mechanisms of action that do not appear to be possible with their glycosylated counterparts. Moreover, the ability to manufacture aglycosylated antibodies in lower eukaryotes or in bacteria provides significant bioprocessing advantages in terms of shorter bioprocess development and running times and by completely bypassing the problems associated with the glycan heterogeneity of conventional antibodies. These advantages are poised to catapult aglycosylated antibodies to the forefront of protein therapeutics.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Similar articles
- With or without sugar? (A)glycosylation of therapeutic antibodies.Hristodorov D, Fischer R, Linden L.Hristodorov D, et al.Mol Biotechnol. 2013 Jul;54(3):1056-68. doi: 10.1007/s12033-012-9612-x.Mol Biotechnol. 2013.PMID:23097175Review.
- Aglycosylated full-length IgG antibodies: steps toward next-generation immunotherapeutics.Ju MS, Jung ST.Ju MS, et al.Curr Opin Biotechnol. 2014 Dec;30:128-39. doi: 10.1016/j.copbio.2014.06.013. Epub 2014 Jul 16.Curr Opin Biotechnol. 2014.PMID:25035939Review.
- Optimal combination of beneficial mutations for improved ADCC effector function of aglycosylated antibodies.Yoon HW, Jo M, Ko S, Kwon HS, Lim CS, Ko BJ, Lee JC, Jung ST.Yoon HW, et al.Mol Immunol. 2019 Oct;114:62-71. doi: 10.1016/j.molimm.2019.07.007. Epub 2019 Jul 20.Mol Immunol. 2019.PMID:31336250
- Engineering Aglycosylated IgG Variants with Wild-Type or Improved Binding Affinity to Human Fc Gamma RIIA and Fc Gamma RIIIAs.Chen TF, Sazinsky SL, Houde D, DiLillo DJ, Bird J, Li KK, Cheng GT, Qiu H, Engen JR, Ravetch JV, Wittrup KD.Chen TF, et al.J Mol Biol. 2017 Aug 4;429(16):2528-2541. doi: 10.1016/j.jmb.2017.07.001. Epub 2017 Jul 8.J Mol Biol. 2017.PMID:28694069Free PMC article.
- Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies.Kayser V, Chennamsetty N, Voynov V, Forrer K, Helk B, Trout BL.Kayser V, et al.Biotechnol J. 2011 Jan;6(1):38-44. doi: 10.1002/biot.201000091.Biotechnol J. 2011.PMID:20949542
Cited by
- Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody.Xu H, Cheng M, Guo H, Chen Y, Huse M, Cheung NK.Xu H, et al.Cancer Immunol Res. 2015 Mar;3(3):266-77. doi: 10.1158/2326-6066.CIR-14-0230-T. Epub 2014 Dec 26.Cancer Immunol Res. 2015.PMID:25542634Free PMC article.
- Revisiting the role of glycosylation in the structure of human IgG Fc.Borrok MJ, Jung ST, Kang TH, Monzingo AF, Georgiou G.Borrok MJ, et al.ACS Chem Biol. 2012 Sep 21;7(9):1596-602. doi: 10.1021/cb300130k. Epub 2012 Jul 10.ACS Chem Biol. 2012.PMID:22747430Free PMC article.
- Recombinant H22(scFv) blocks CD64 and prevents the capture of anti-TNF monoclonal antibody. A potential strategy to enhance anti-TNF therapy.Hristodorov D, Mladenov R, Brehm H, Fischer R, Barth S, Thepen T.Hristodorov D, et al.MAbs. 2014;6(5):1283-9. doi: 10.4161/mabs.32182.MAbs. 2014.PMID:25517313Free PMC article.
- With or without sugar? (A)glycosylation of therapeutic antibodies.Hristodorov D, Fischer R, Linden L.Hristodorov D, et al.Mol Biotechnol. 2013 Jul;54(3):1056-68. doi: 10.1007/s12033-012-9612-x.Mol Biotechnol. 2013.PMID:23097175Review.
- Current Status: Site-Specific Antibody Drug Conjugates.Schumacher D, Hackenberger CP, Leonhardt H, Helma J.Schumacher D, et al.J Clin Immunol. 2016 May;36 Suppl 1:100-7. doi: 10.1007/s10875-016-0265-6. Epub 2016 Mar 22.J Clin Immunol. 2016.PMID:27003914Free PMC article.Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources